D. E. Shaw & Co. Inc. reduced its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 55.0% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 56,534 shares of the company's stock after selling 69,227 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.15% of iTeos Therapeutics worth $434,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in ITOS. Virtus ETF Advisers LLC increased its stake in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock worth $69,000 after acquiring an additional 3,293 shares during the last quarter. SG Americas Securities LLC increased its position in shares of iTeos Therapeutics by 12.2% during the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock valued at $106,000 after purchasing an additional 1,508 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of iTeos Therapeutics by 16.9% during the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock valued at $128,000 after purchasing an additional 2,402 shares during the last quarter. US Bancorp DE increased its position in shares of iTeos Therapeutics by 40.1% during the 4th quarter. US Bancorp DE now owns 16,919 shares of the company's stock valued at $130,000 after purchasing an additional 4,843 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of iTeos Therapeutics during the 4th quarter valued at about $142,000. 97.16% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on the company. Piper Sandler reiterated an "overweight" rating and set a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Raymond James set a $12.00 target price on iTeos Therapeutics in a report on Wednesday, May 14th. Leerink Partnrs cut iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 14th. JPMorgan Chase & Co. cut iTeos Therapeutics from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $15.00 to $8.00 in a report on Tuesday, May 13th. Finally, Leerink Partners restated a "market perform" rating and set a $9.00 target price (down from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, iTeos Therapeutics presently has an average rating of "Hold" and an average target price of $15.86.
View Our Latest Report on iTeos Therapeutics
iTeos Therapeutics Trading Down 0.5%
NASDAQ ITOS traded down $0.05 on Friday, hitting $9.98. The company's stock had a trading volume of 1,603,934 shares, compared to its average volume of 644,386. iTeos Therapeutics, Inc. has a 52-week low of $4.80 and a 52-week high of $18.13. The company's 50-day simple moving average is $6.99 and its 200 day simple moving average is $7.40. The firm has a market cap of $381.97 million, a P/E ratio of -3.17 and a beta of 1.39.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.14. On average, research analysts forecast that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.
Insiders Place Their Bets
In other iTeos Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the sale, the insider now owns 2,108,594 shares in the company, valued at approximately $16,995,267.64. This trade represents a 23.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total value of $8,317,363.86. Following the completion of the sale, the insider now owns 3,452,797 shares of the company's stock, valued at approximately $27,829,543.82. This trade represents a 23.01% decrease in their position. The disclosure for this sale can be found here. Company insiders own 12.50% of the company's stock.
About iTeos Therapeutics
(
Free Report)
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Featured Articles
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
